# Effect of Tofacitinib in Treating ANCA-associated Vasculitis

> **NCT04973033** · NA · COMPLETED · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 10 (actual)

## Conditions studied

- ANCA Associated Vasculitis
- Drug Use
- JAK-STAT Pathway Deregulation

## Interventions

- **DRUG:** Tofacitinib

## Key facts

- **NCT ID:** NCT04973033
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-01
- **Primary completion:** 2021-01-31
- **Final completion:** 2021-01-31
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04973033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04973033, "Effect of Tofacitinib in Treating ANCA-associated Vasculitis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04973033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*